A partnership with the prestigious Cleveland Clinic Ohio and FDA 510(k) clearance for an innovative clinical decision support software solution are just two of the latest successes for members of ABHI’s US Accelerator programme.
Owing to their strong international reputation in the anaesthesia and airway management field, UK innovator P3 Medical were chosen by Cleveland Clinic Ohio’s Cardiothoracic Anaesthesia department to develop a ground-breaking airway device that improves patient safety.
The pioneering MK Airway, which is set to be brought to market by 2021, is an intubating airway consisting of a rigid, non-crushable conduit and bite guard for endoscopic tracheal intubations.
What sets MK Airway aside from existing airway devices is the addition of an articulating channel and bite block, which permits it to be removed from a bronchoscope without disrupting the placement of an endotracheal tube- a complication that can jeopardise the procedure and patient safety.
Adrian Javes, Sales Director from P3 said: “P3 Medical products are used in operating theatres throughout the world so we were the ideal partner to deliver the hospital’s vision. It has been a fantastic opportunity to work with the Cleveland Clinic on a device that will dramatically change clinical care for patients around the world. It’s a great example of Britain and the US working together to improve global patient care.”
Another UK healthcare company who has received positive notification in the United States this week is Directed Systems Ltd, who have received 510(k) clearance from The US Food and Drug Administration (FDA) for their pioneering Hypotension Decision Assist (HDA) software.
The innovative clinical decision support software solution assists anesthesiologists to manage blood pressure and the cardiovascular system during surgery. It can now be marketed for use in operating rooms across the United States.
Mark Leaning, CEO & Founder: “We are delighted to receive FDA 510(k) clearance of Hypotension Decision Assist (HDA) which marks a true milestone for Directed Systems as a business. Not only does this allow us to now begin marketing and sales of HDA in the United States, but it is tremendous validation of our Product Development to date.”
P3 Medical and Directed Systems are being supported with their US Strategy by the Association of British HealthTech Industries (ABHI) and are part of ABHI’s US Accelerator programme in partnership with Dell Medical School.
The AHSN Network is an active partner in the ABHI’s US Accelerator, with a number of the programme’s members having worked with the AHSNs to accelerate their activity in the UK. AHSN colleagues have also supported UK companies on ABHI’s tailored US trade missions, such as P3, and providing critical insights into the UK health system and contributing to shared learning initiatives.
This week P3 Medical and Directed Systems join 12 other UK companies in Dallas, San Antonio and Austin to showcase their technologies and meet with the State’s most influential and senior healthcare figures.
Over the last five years, ABHI’s missions to Texas have helped UK companies develop and strengthen partnerships across the State with a variety of organisations including academic, investor communities and professional service providers. Outcomes from the mission have included clinical trials, research collaborations, new partnerships and sales.
Paul Benton, ABHI’s Managing Director, International, said: “The UK is a world leader in health innovation and digital tech like this really highlights why. It has been great to support P3 and Directed Systems with their US Strategies and to be able to showcase their software to senior US healthcare figures as a cutting-edge examples of British technology.”